Meg Perumal1, Euan A Stronach, Hani Gabra, Eric O Aboagye. 1. Comprehensive Cancer Imaging Centre, Department of Cancer & Surgery, Faculty of Medicine, Imperial College London, Hammersmith Hospital, 240 MRC Cyclotron Building, Du Cane Road, London, W12 0NN, UK.
Abstract
PURPOSE: We evaluated whether 2-deoxy-2-[(18)F]fluoro-D-glucose ([(18)F]FDG) and 3'-deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) positron emission tomography (PET) could be used as imaging biomarkers of platinum resensitization in ovarian cancer. PROCEDURES: Paired platinum-sensitive and platinum-resistant ovarian cancer cells from the same patient, PEO1 and PEO4, grown as tumor xenografts in nude mice, were assessed by PET. RESULTS: The AKT inhibitor, API-2, resensitized platinum-resistant PEO4 tumors to cisplatin, leading to a markedly lower Ki67 labeling index (p ≤ 0.006, n = 6 per group). [(18)F]FDG-PET and [(18)F]FLT-PET imaging variables were lower after combination treatment compared with vehicle treatment (p ≤ 0.006, n = 6 per group). No changes were seen with either drug alone. PRAS40 phosphorylation status was a sensitive biochemical marker of pathway inhibition, whereas reductions thymidine kinase 1 expression defined the [(18)F]FLT response. CONCLUSIONS: Therapeutic inhibition of AKT activation in acquired platinum-resistant disease can be imaged noninvasively by [(18)F]FDG-PET and [(18)F]FLT-PET warranting further assessment.
PURPOSE: We evaluated whether 2-deoxy-2-[(18)F]fluoro-D-glucose ([(18)F]FDG) and 3'-deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) positron emission tomography (PET) could be used as imaging biomarkers of platinum resensitization in ovarian cancer. PROCEDURES: Paired platinum-sensitive and platinum-resistant ovarian cancer cells from the same patient, PEO1 and PEO4, grown as tumor xenografts in nude mice, were assessed by PET. RESULTS: The AKT inhibitor, API-2, resensitized platinum-resistant PEO4 tumors to cisplatin, leading to a markedly lower Ki67 labeling index (p ≤ 0.006, n = 6 per group). [(18)F]FDG-PET and [(18)F]FLT-PET imaging variables were lower after combination treatment compared with vehicle treatment (p ≤ 0.006, n = 6 per group). No changes were seen with either drug alone. PRAS40 phosphorylation status was a sensitive biochemical marker of pathway inhibition, whereas reductions thymidine kinase 1 expression defined the [(18)F]FLT response. CONCLUSIONS: Therapeutic inhibition of AKT activation in acquired platinum-resistant disease can be imaged noninvasively by [(18)F]FDG-PET and [(18)F]FLT-PET warranting further assessment.
Authors: Nelson Rhodes; Dirk A Heerding; Derek R Duckett; Derek J Eberwein; Victoria B Knick; Timothy J Lansing; Randy T McConnell; Tona M Gilmer; Shu-Yun Zhang; Kimberly Robell; Jason A Kahana; Robert S Geske; Elena V Kleymenova; Anthony E Choudhry; Zhihong Lai; Jack D Leber; Elisabeth A Minthorn; Susan L Strum; Edgar R Wood; Pearl S Huang; Robert A Copeland; Rakesh Kumar Journal: Cancer Res Date: 2008-04-01 Impact factor: 12.701
Authors: S P Langdon; S S Lawrie; F G Hay; M M Hawkes; A McDonald; I P Hayward; D J Schol; J Hilgers; R C Leonard; J F Smyth Journal: Cancer Res Date: 1988-11-01 Impact factor: 12.701
Authors: Lin Yang; Han C Dan; Mei Sun; Qiyuan Liu; Xia-meng Sun; Richard I Feldman; Andrew D Hamilton; Mark Polokoff; Santo V Nicosia; Meenhard Herlyn; Said M Sebti; Jin Q Cheng Journal: Cancer Res Date: 2004-07-01 Impact factor: 12.701
Authors: S L Cooke; C K Y Ng; N Melnyk; M J Garcia; T Hardcastle; J Temple; S Langdon; D Huntsman; J D Brenton Journal: Oncogene Date: 2010-06-28 Impact factor: 9.867
Authors: Julius Leyton; John R Latigo; Meg Perumal; Harmandeep Dhaliwal; Qimin He; Eric O Aboagye Journal: Cancer Res Date: 2005-05-15 Impact factor: 12.701
Authors: Euan A Stronach; Albandri Alfraidi; Nona Rama; Christoph Datler; James B Studd; Roshan Agarwal; Tankut G Guney; Charlie Gourley; Bryan T Hennessy; Gordon B Mills; Antonello Mai; Robert Brown; Roberto Dina; Hani Gabra Journal: Cancer Res Date: 2011-05-13 Impact factor: 12.701
Authors: H Barthel; H Wilson; D R Collingridge; G Brown; S Osman; S K Luthra; F Brady; P Workman; P M Price; E O Aboagye Journal: Br J Cancer Date: 2004-06-01 Impact factor: 7.640
Authors: Sonja Schelhaas; Kathrin Heinzmann; Vikram R Bollineni; Gerbrand M Kramer; Yan Liu; John C Waterton; Eric O Aboagye; Anthony F Shields; Dmitry Soloviev; Andreas H Jacobs Journal: Theranostics Date: 2017-01-01 Impact factor: 11.556